BACKGROUND: Anaerobic bacteria are increasingly regarded as important in cystic fibrosis (CF) pulmonary infection. The aim of this study was to determine the effect of antibiotic treatment on aerobic and anaerobic microbial community diversity and abundance during exacerbations in patients with CF. METHODS: Sputum was collected at the start and completion of antibiotic treatment of exacerbations and when clinically stable. Bacteria were quantified and identified following culture, and community composition was also examined using culture-independent methods. RESULTS: Pseudomonas aeruginosa or Burkholderia cepacia complex were detected by culture in 24/26 samples at the start of treatment, 22/26 samples at completion of treatment and 11/13 stable samples. Anaerobic bacteria were detected in all start of treatment and stable samples and in 23/26 completion of treatment samples. Molecular analysis showed greater bacterial diversity within sputum samples than was detected by culture; there was reasonably good agreement between the methods for the presence or absence of aerobic bacteria such as P aeruginosa (κ=0.74) and B cepacia complex (κ=0.92), but agreement was poorer for anaerobes. Both methods showed that the composition of the bacterial community varied between patients but remained relatively stable in most individuals despite treatment. Bacterial abundance decreased transiently following treatment, with this effect more evident for aerobes (median decrease in total viable count 2.3×10(7) cfu/g, p=0.005) than for anaerobes (median decrease in total viable count 3×10(6) cfu/g, p=0.046). CONCLUSION: Antibiotic treatment targeted against aerobes had a minimal effect on abundance of anaerobes and community composition, with both culture and molecular detection methods required for comprehensive characterisation of the microbial community in the CF lung. Further studies are required to determine the clinical significance of and optimal treatment for these newly identified bacteria.
BACKGROUND: Anaerobic bacteria are increasingly regarded as important in cystic fibrosis (CF) pulmonary infection. The aim of this study was to determine the effect of antibiotic treatment on aerobic and anaerobic microbial community diversity and abundance during exacerbations in patients with CF. METHODS: Sputum was collected at the start and completion of antibiotic treatment of exacerbations and when clinically stable. Bacteria were quantified and identified following culture, and community composition was also examined using culture-independent methods. RESULTS:Pseudomonas aeruginosa or Burkholderia cepacia complex were detected by culture in 24/26 samples at the start of treatment, 22/26 samples at completion of treatment and 11/13 stable samples. Anaerobic bacteria were detected in all start of treatment and stable samples and in 23/26 completion of treatment samples. Molecular analysis showed greater bacterial diversity within sputum samples than was detected by culture; there was reasonably good agreement between the methods for the presence or absence of aerobic bacteria such as P aeruginosa (κ=0.74) and B cepacia complex (κ=0.92), but agreement was poorer for anaerobes. Both methods showed that the composition of the bacterial community varied between patients but remained relatively stable in most individuals despite treatment. Bacterial abundance decreased transiently following treatment, with this effect more evident for aerobes (median decrease in total viable count 2.3×10(7) cfu/g, p=0.005) than for anaerobes (median decrease in total viable count 3×10(6) cfu/g, p=0.046). CONCLUSION: Antibiotic treatment targeted against aerobes had a minimal effect on abundance of anaerobes and community composition, with both culture and molecular detection methods required for comprehensive characterisation of the microbial community in the CF lung. Further studies are required to determine the clinical significance of and optimal treatment for these newly identified bacteria.
Authors: Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh Journal: Am J Respir Crit Care Med Date: 2012-02-03 Impact factor: 21.405
Authors: Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma Journal: Ann Am Thorac Soc Date: 2013-06
Authors: Katherine E Price; Amanda A Naimie; Edward F Griffin; Charles Bay; George A O'Toole Journal: J Bacteriol Date: 2015-10-19 Impact factor: 3.490
Authors: Laura J Sherrard; Bettina Schaible; Kathryn A Graham; Stef J McGrath; Leanne McIlreavey; Joseph Hatch; Matthew C Wolfgang; Marianne S Muhlebach; Deirdre F Gilpin; Thamarai Schneiders; J Stuart Elborn; Michael M Tunney Journal: J Antimicrob Chemother Date: 2014-06-10 Impact factor: 5.790
Authors: Marianne S Muhlebach; Joseph E Hatch; Gisli G Einarsson; Stef J McGrath; Deirdre F Gilipin; Gillian Lavelle; Bojana Mirkovic; Michelle A Murray; Paul McNally; Nathan Gotman; Sonia Davis Thomas; Matthew C Wolfgang; Peter H Gilligan; Noel G McElvaney; J Stuart Elborn; Richard C Boucher; Michael M Tunney Journal: Eur Respir J Date: 2018-07-11 Impact factor: 16.671